In the subsequent sections, we will review available data and describe the biology of the HER2 pathway in normal and tumorigenesis processes, trying to provide a comprehensive overview of its dysregulation, clinical implications, as well as recent studies of emerging therapies for NSCLC patients with HER2 alterations. The gene discussed is ERBB2; the disease is non-small cell lung carcinoma.